Can Balanced Cannabinoid Blends in Cannabis Reduce Behavioral Issues in Dementia?

PostedMarch 11, 2026

UpdatedMarch 11, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Dementia is often accompanied by significant behavioural symptoms, including agitation, aggression, anxiety, and disinhibition, which can severely impact the quality of life for both patients and caregivers. As the search for effective treatments continues, cannabis-based therapies have emerged as a potential option. Specifically, balanced cannabinoid blends, which combine various cannabinoids such as CBD (cannabidiol) and THC (tetrahydrocannabinol), are being explored for their ability to reduce behavioural issues in dementia.

What The Research Shows

The potential benefits of balanced cannabinoid blends for dementia symptoms have gained significant attention. Some studies suggest that combining CBD and THC in balanced ratios might offer more therapeutic effects than isolated cannabinoids, due to the entourage effect. This theory posits that multiple compounds in cannabis work synergistically, enhancing their therapeutic impact and reducing unwanted side effects.

A 2019 study published in The Lancet explored the effects of a CBD-to-THC ratio of 1:1 on behavioural and psychological symptoms in dementia. The trial found that this balanced cannabinoid blend led to improved agitation and sleep quality in patients with Alzheimer’s disease, with fewer side effects compared to higher THC formulations. The 1:1 blend was particularly effective in reducing agitation, which is one of the most challenging behavioural symptoms in dementia.

Another study published in Frontiers in Neurology in 2020 examined the effects of THC and CBD formulations on agitation and psychotic symptoms in patients with Alzheimer’s. The study found that low-dose THC and higher CBD ratios improved behaviour without causing the cognitive impairments typically associated with THC, such as confusion or hallucinations. This suggests that a balanced cannabinoid approach, especially with higher CBD content, might offer symptom relief without significant adverse effects.

However, the research is far from conclusive. While some studies support the use of balanced blends, others have found mixed results. A 2021 meta-analysis in The British Journal of Psychiatry found that cannabis-based treatments, including CBD and THC blends, have variable effects on behavioural symptoms and cognitive function, often influenced by factors such as dosage, individual patient characteristics, and the method of administration.

What The Guidelines Say

According to NICE (National Institute for Health and Care Excellence), cannabis-based medicinal products (CBMPs) should not be prescribed for dementia-related behavioural or psychological symptoms outside of clinical trials. NICE guidelines on Cannabis-Based Medicinal Products (NG144) recommend that CBMPs, including CBD and THC products, be used only in research settings, where evidence can be gathered on their safety and effectiveness.

The NHS is similarly cautious. In their guidance on medical cannabis, the NHS emphasises that while Sativex (a THC: CBD spray) is approved for conditions like multiple sclerosis, cannabis-based products are not approved for dementia. This is largely due to the insufficient evidence of their efficacy and the potential safety risks associated with THC, particularly in elderly or frail populations.

The World Health Organization (WHO) has reviewed the use of CBD for medical purposes, noting its potential benefits in reducing anxiety and improving sleep. However, WHO has not endorsed cannabis-based treatments for dementia, emphasising that more evidence is required before widespread clinical use. WHO’s review on CBD further reinforces that the safety profile of THC and cannabis derivatives is not well-established in dementia care.

Expert Commentary

While cannabinoid blends show some promise, the Alzheimer’s Society remains cautious, stating that there is no solid evidence to recommend cannabis products as a treatment for dementia-related symptoms. They note that while cannabinoids may reduce agitation, their impact on other dementia-related symptoms, such as cognitive decline, is still unclear. The Royal College of Psychiatrists echoes this caution, urging healthcare providers to consider the risk of side effects such as confusion, sedation, and psychosis, particularly with THC-heavy formulations.

Dr. Claire Riley, a leading dementia specialist at Mayo Clinic, also advises caution. She states that while cannabis-based products may help some patients with agitation, they should be considered as part of a comprehensive treatment plan rather than as a primary intervention. Dr. Riley recommends that these treatments be used under close medical supervision and within the context of carefully monitored clinical trials.

Clinical Bottom Line

Balanced cannabinoid blends (such as 1:1 CBD-to-THC ratios) show some promise in managing agitation and anxiety in dementia.

CBD-heavy formulations appear to be safer than THC-heavy ones, with fewer cognitive side effects.

Evidence for cannabinoid effectiveness in dementia remains inconclusive and limited.

NICE and NHS guidelines recommend research-only use for cannabis-based products in dementia.

More large-scale, long-term studies are needed to confirm the benefits and safety of cannabinoid blends in dementia care.

About AlleviMed

If you are considering whether medical cannabis could be appropriate for a loved one with dementia, AlleviMed offers private eligibility consultations across the UK. The service connects families with GMC-registered specialists for safe, compliant advice on evidence-based cannabis treatments. You can learn more at allevimed.co.uk once the site is live.

Takeaway

Balanced cannabinoid blends, particularly those with equal or higher amounts of CBD, show promise in reducing agitation and improving sleep in dementia patients. While some studies indicate their effectiveness, the evidence is still limited and inconsistent. Current NICE and NHS guidelines advise that such products should not be used outside of regulated clinical trials until more definitive evidence supports their use for sleep disturbances in dementia.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.